Skip to main content
Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

HOME
ABOUT
AREAS OF FOCUS
- Close
- PIPELINE
- POSTERS & PUBLICATIONS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
CONTACT US

Main Content

ADVANCING ANTIBODY DRUG

CONJUGATES WITH NOVEL

IMMUNO-ONCOLOGY PAYLOADS

CORPORATE PRESENTATION CORPORATE PRESENTATION GENERAL MEETING 2026 GENERAL MEETING 2026

RECENT PRESS RELEASES

Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers

October 1, 2026

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

September 8, 2026

Akari Therapeutics Participates in the Virtual Investor “Why Now” On-Demand Conference

August 27, 2026

Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

August 18, 2026

Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform

August 13, 2026

Footer

FOLLOW US

Privacy Statement

Copyright © 2026 · Akari Therapeutics · Site Designed by Polus Digital, Inc.